| http://www.w3.org/ns/prov#value | - Factors that might cause material differences include, among others: failure or delay in the commencement or completion of our preclinical studies and clinical trials which may be caused by several factors, including: risks related to the commercialization efforts for taliglucerase alfa in the United States, Israel, Brazil and other countries in which it is approved for sale; risks relating to the
|
